CN103550281A - Medicine composition for preventing and treating diabetes and diabetes complications and preparation thereof - Google Patents
Medicine composition for preventing and treating diabetes and diabetes complications and preparation thereof Download PDFInfo
- Publication number
- CN103550281A CN103550281A CN201310562432.7A CN201310562432A CN103550281A CN 103550281 A CN103550281 A CN 103550281A CN 201310562432 A CN201310562432 A CN 201310562432A CN 103550281 A CN103550281 A CN 103550281A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- diabetes
- fructus momordicae
- momordicae charantiae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a medicine composition for preventing and treating diabetes and diabetes complications. The medicine composition for preventing and treating the diabetes and diabetes complications comprises the following components in parts by weight: 40-120 parts of panax notoginseng extract, 60-180 parts of American ginseng extract, 0.2-0.6 parts of chromium picolinate and 10-70 parts of momordica charantia extract. The medicine composition can be used for reducing blood sugar and effectively inhibiting a non-enzyme glycosylation reaction of protein, so that diabetes complications of atherosclerosis, diabetic nephropathy, diabetes cardiovascular diseases, diabetes retinal diseases and the like which are caused by non-enzyme glycosylation of the protein can be effectively prevented and treated. The invention also provides a preparation which is prepared from the medicine composition and is used for preventing and treating the diabetes and diabetes complications.
Description
Technical field
The present invention relates to the pharmaceutical composition of a kind of prevention and treatment diabetes and complication thereof, and the preparation of being prepared by this pharmaceutical composition.
Background technology
Diabetes are whole body chronic progressive diseases that metabolism disorder causes, and belong to the traditional Chinese medical science category of quenching one's thirst.In recent years, along with the raising of people's living standard and the change of life style, the sickness rate of diabetes is the trend of remarkable rising, has become the third-largest disease after malignant tumor and cardiovascular disease, and the mankind's health in serious threat.Diabetes are to continue a kind of complex disease that hyperglycemia is basic biochemical character.Lasting hyperglycemia state can cause non-enzymatic glycation in body to accelerate, thereby causes nonenzymatic glycosylation dead end product accumulating in vivo.Nonenzymatic glycosylation dead end product can change protein structure and function, affects lipid metabolism, modification of nucleic acids and induced oxidation stress, be the principal element that diabetic complication occurs.Protein non-enzyme glycosylation can't stop because blood glucose is controlled, final like this generation and the development that can cause chronic complicating diseases of diabetes, causes diabetic nephropathy etc. as atherogenesis, cardiopulmonary compliance lower, lenticular opacity causes cataract, glomerular basement membrane permeability raises.People focused on the control of blood glucose to the treatment of diabetes in the past, but along with going deep into of studying, protein non-enzyme glycosylation reaction is subject to people's attention day by day with the relation of diabetic complication.The non-enzymatic glycation of body internal protein is relevant with the pathomechanism of a lot of complication, thereby is the New Policy in pharmacotherapeutics field in recent years by the generation development that blocking-up non-enzymatic glycation is prevented and treated above-mentioned disease.
Research both domestic and external shows, diabetes and complication thereof are the diseases that can control, and selecting best Scientific Treatment method is the key of preventing and treating diabetes and complication thereof.At present, treatment diabetes are on the basis of diet and exercise therapy, doctor trained in Western medicine adopts the methods such as oral antidiabetic drug (sulphanylureas, biguanides) or insulin injection more, although this can reduce blood glucose effectively, but most of blood sugar lowering Western medicine still rests on the stage of curing the symptoms, not the disease, and can cause diabetics to produce drug resistance, and cause hypoglycemia, merge the multiple toxic and side effects in various degree such as renal function reduction, accelerated generation and the development of diabetic complication.
Chinese medicine is having its clear superiority in treatment aspect diabetes, and Recent study finds, the reduction blood glucose effect side effect of Chinese medicine is little, has manifold effect, multidigit point and the advantage such as multi-functional.In recent years, research worker has been utilized the raw material of several integration of edible and medicinal herbs such as Radix Ginseng, Fructus Momordicae charantiae to propose some to have health food and the medicine that improves blood glucose function, but blood sugar decreasing effect is still not ideal enough, and especially, aspect prevention and complication, curative effect is not remarkable.
The present invention, just based on above-mentioned background technology, proposes a kind of pharmaceutical composition that can significantly reduce blood glucose and can prevent and treat diabetic complication, for the control of diabetes is offered help.
Summary of the invention
The object of the invention is to: the pharmaceutical composition that a kind of prevention and treatment diabetes and complication thereof are provided.
The present invention also aims to: the preparation of preventing and treating diabetes of preparing with described Chinese medicine composition is provided.
Object of the present invention is achieved through the following technical solutions:
The pharmaceutical composition that a kind of prevention and treatment diabetes and complication thereof are provided, it is comprised of the component of following weight proportion:
The Radix Notoginseng extract of 40～120 parts, the Radix Panacis Quinquefolii extract of 60～180 parts, the chromium picolinate of 0.2～0.6 part and the Fructus Momordicae charantiae extract of 10～70 parts.
Described Chinese medicine composition, preferably the component by following weight proportion forms: the Radix Notoginseng extract of 40～100 parts, the Radix Panacis Quinquefolii extract of 80～150 parts, the chromium picolinate of 0.3～0.6 part and the Fructus Momordicae charantiae extract of 25～60 parts.
Described Chinese medicine composition, further the preferred component by following weight proportion forms: the Radix Notoginseng extract of 60～80 parts, the Radix Panacis Quinquefolii extract of 80～100 parts, the chromium picolinate of 0.4～0.5 part and the Fructus Momordicae charantiae extract of 25～50 parts.
A kind of most preferred pharmaceutical composition of the present invention, is comprised of the component of following weight proportion: the Radix Notoginseng extract of 60 parts, the Radix Panacis Quinquefolii extract of 80 parts, the chromium picolinate of 0.41 part and the Fructus Momordicae charantiae extract of 50 parts.
The another kind of most preferred pharmaceutical composition of the present invention, is comprised of the component of following weight proportion: the Radix Notoginseng extract of 75 parts, the Radix Panacis Quinquefolii extract of 80 parts, the chromium picolinate of 0.5 part and the Fructus Momordicae charantiae extract of 35 parts.
Another most preferred pharmaceutical composition of the present invention, is comprised of the component of following weight proportion: the Radix Notoginseng extract of 70 parts, the Radix Panacis Quinquefolii extract of 95 parts, the chromium picolinate of 0.45 part and the Fructus Momordicae charantiae extract of 25 parts.
In described Chinese medicine composition, Radix Notoginseng extract derives from panax araliaceae plant Panax notoginseng(Burk.) root extract of F.H.Chen is brown color powder; Radix Panacis Quinquefolii extract derives from the root extract of Araliaceae Radix Panacis Quinquefolii Panax quinque folium L., is brown ceramic powder shape product; Fructus Momordicae charantiae extract derives from the fruit extract of cucurbitaceous plant Fructus Momordicae charantiae Momordica Charantia L., is brown ceramic powder; Chromium picolinate (Chromium picolinate) molecular formula is Cr (C
6h
4nO
2)
3, molecular weight is 418.33, this strain aubergine crystallinity fine powder.
Extract in described Chinese medicine composition is commercially available acquisition all, and the preparation method of described Chinese medicine composition is by the simple mixing of described several Chinese medicine extract.
The present invention also provides the preparation of preventing and treating diabetes and complication thereof of preparing with described Chinese medicine composition.
Described preparation contains described Chinese medicine composition and conventional adjuvant, and wherein said adjuvant accounts for 15%～65% of total formulation weight amount.
Described adjuvant can be one or more in disintegrating agent, filler, lubricant, correctives or excipient.Wherein said disintegrating agent can be starch; Described filler can be starch or dextrin; Described lubricant can be magnesium stearate; Described correctives can be lactose; Described excipient can be microcrystalline Cellulose.
The dosage form of described preparation can be hard capsule, tablet or granule.
For example can with Chinese medicine composition preparation of the present invention, prevent and treat the hard capsule preparation of diabetes and complication thereof in accordance with the following methods:
Step 1: take Radix Notoginseng extract, Radix Panacis Quinquefolii extract, Fructus Momordicae charantiae extract, the chromium picolinate being up to the standards by formula proportion;
Step 2: add appropriate filler, disintegrating agent, mix homogeneously;
Step 3: be filled to capsule with Autocapsulefillingmachine;
Step 4: by above-mentioned capsule granulate, polishing, packing.
In step 2, indication filler, disintegrating agent are the common medicinal supplementary material that meets the standard code of 2010 editions < < Chinese Pharmacopoeia > > pharmaceutic adjuvants, as starch etc.
The Radix Notoginseng extract main component that the present invention adopts is Radix Notoginseng total arasaponins; there is obvious blood vessel dilating, improve hemodynamics, suppress thrombosis, reduce the effect of myocardial oxygen consumption; myocardial cell ischemia injury is had to direct protective effect; clinically be usually used in treating coronary heart disease, arrhythmia, apoplexy and apoplexy sequela, the cardiovascular pathological changes that diabetes are caused and diabetic nephropathy have good therapeutical effect.Radix Panacis Quinquefolii extract can stimulate by suppressing the activity of mitochondrion UCP-2 the generation of insulin, the loss of prevention β cell, improve ATP level, cloning Bcl-2 is increased, lower short apoptosis factor Caspase-9 simultaneously, reduce apoptotic generation, thereby improve the blood sugar level of diabetics.Radix Panacis Quinquefolii also has the formation of Profilin matter nonenzymatic glycosylation end-product (AGEs), changes platelet adhesion reaction and coherent condition, has the microcirculation of improvement, anticoagulation and prevents thrombosis effect, and diabetic complication is had to good preventive and therapeutic action.Fructus Momordicae charantiae extract has stimulating activity G emiocytosis insulin, para-insulin effect and promotes the synthetic effect of liver glycogen.Chromium picolinate, trivalent chromium is the important component part of glucose tolerance factor (GTF), can by cell membrane, directly act on histiocyte smoothly, increase insulin active (sensitivity), making it active strengthens, involved in sugar metabolic process, prevents safely and effectively because insulin produces or the under-utilized blood sugar increasing causing, thereby makes it to become the effective ingredient of auxiliary adjustment blood sugar in diabetic patients level.
Pharmaceutical composition of the present invention, on prior art basis, passes through lot of experiments and gropes and find, by regulating the ratio of above-mentioned several components to reach after particular range, the blood sugar decreasing effect of compositions can access significant lifting.Specifically, the inventor finds in test, after Radix Notoginseng extract, Radix Panacis Quinquefolii extract and Fructus Momordicae charantiae extract compatibility, can produce synergism, significantly reduces blood sugar level.But the inventor also further finds, is three's compatibility equally, the synergism under different proportion compatibilities is significantly different.Particularly when the ratio of Fructus Momordicae charantiae extract is during higher than Radix Notoginseng extract and Radix Panacis Quinquefolii extract, not only its whole hypoglycemic activity is starkly lower than Fructus Momordicae charantiae extract ratio lower than the compatibility of Radix Notoginseng extract and Radix Panacis Quinquefolii extract, and, aspect Profilin matter non-enzymatic glycation, effect is especially remarkable.Therefore, the inventor has obtained the formula of pharmaceutical composition of the present invention through lot of experiments screening, and through experimental verification this pharmaceutical composition remarkable blood sugar lowering, the Profilin matter non-enzymatic glycation effect that have.
The efficacy test result of Chinese medicine composition of the present invention is as follows:
1. experiment material
1.1 test specimen
Given the test agent: the product of the embodiment of the present invention 1 preparation.
High Fructus Momordicae charantiae content reference substance: the product that Radix Notoginseng extract 40g, Radix Panacis Quinquefolii extract 40g, chromium picolinate 0.45g, Fructus Momordicae charantiae extract 130g, starch 189.55g are prepared through the embodiment of the present invention 1 same procedure.
1.2 laboratory animal
Male mice in kunming, body weight (20.0 ± 2.0) g are provided by Hubei Province's Experimental Animal Center.
1.3 instruments and reagent
1.3.1 instrument RF-5301PC spectrofluorophotometer (Japanese Shimadzu company), UV-2501 ultraviolet-visible spectrophotometer (Japanese Shimadzu company).
1.3.2 reagent aminoguanidine Hemisulphate, alloxan are purchased from Sigma company; Bovine serum albumin is purchased from Jiang Lai bio tech ltd, Shanghai.Glucose assays test kit is purchased from Sen Beijia bio tech ltd, Nanjing.All the other experimental drugs are commercially available analytical pure.
1.4 dosage designs
Being subject to test product human body recommended amounts is 0.02g/kgBW, establishes low, high two dosage given the test agent groups with these 10,20 times, is respectively 0.2,0.4g/kgBW.High Fructus Momordicae charantiae content matched group is established 0.4g/kgBW dosage group.
2. method
2.1 external protein non-enzyme glycosylation reaction and mensuration
The pH7.2 phosphate buffer of take is prepared whole mass concentration as the liquid of 5.0g/L bovine serum albumin, 3mmol/L sodium azide and 1mol/L glucose.Pharmaceutical intervention group in glycosylation system, add aminoguanidine, be subject to test product or high Fructus Momordicae charantiae content reference substance, wherein, aminoguanidine group is for containing aminoguanidine 4mmol/L, be subject to that test product component is 0.2, two groups of 0.4g/kgBW, high Fructus Momordicae charantiae content matched group is 0.4g/kgBW, in blank group reaction system, do not add glucose, respectively at hatching continuously 7～28d under 37 ℃ of constant temperature lucifuge conditions.Respectively at 7,14,21,28d gets different experiments group sample and preserves to be measured in-70 ℃ of refrigerator freezings.Glycosylated protein can produce fluorescence, and this experimentation understands by measuring the situation of change of fluorescence-causing substance the inhibition situation that is subject to test product.Each sample is through fluorescence spectrophotometry assay.Each parameter is respectively excitation wavelength 370nm, emission wavelength 440nm, sensitivity 2, gain 5, stitch wide 5nm.
2.2 in body zoopery
Disposable tail vein injection alloxan 80mg/kg, makes diabetic mice model.Fasting 3h after 5 days, gets blood from survival mice vena ophthalmica, and surveying blood glucose value is that 16～25mmol/L person is selected.Get 40 of qualified mices, be divided at random model group, high Fructus Momordicae charantiae content group, be subject to test product low dose group and be subject to test product high dose group, 10 every group, separately get 10 of healthy mices and make Normal group.Normal mouse group, model group and be subject to test product group with normal saline and Fructus Momordicae charantiae extract, to carry out gastric infusion respectively, every day 1 time, continuously 30d.Last administration fasting 5h, surveys fasting glucose, relatively each treated animal blood glucose value and blood glucose down ratio.Each organizes mice gavage 2.0g/kgBW glucose solution again, respectively at getting tail blood measuring blood value after 0h, 0.5h, 2h, observe tested material on alloxan hyperglycemia model mice glucose load after the impact of blood glucose and carbohydrate tolerance.After fasting 12h, put to death and respectively organize mice, cut open the belly rapidly and take out the heart, liver, kidney, in-70 ℃ of refrigerator freezings, preserve, to be measured.
The mensuration of nonenzymatic glycosylation product in 2.3 hearts, liver, nephridial tissue
Tissue is shredded, add chloroform-methanol (2:1) 5mL degrease in homogenate, centrifugation, 4 ℃ of shakes spend the night, and through aquation, rinse, and at HEPES buffer, spend the night, and add collagenase, 37 ℃ of concussion digestion 24h.Centrifuging and taking supernatant, spectrofluorophotometer is measured fluorescence intensity at 370nm/440nm place.Take HEPES buffer fluorescent value as any flat fluorescent AUF, and fluorescent intensity is converted according to this.
2.4 statistical procedures
Application SPSS11.5 statistical software carries out date processing, and group difference significance relatively adopts t check.P < 0.05 has statistical significance.
3 results
The inhibitory action of 3.1 pairs of external protein non-enzyme glycosylations
Experiment in vitro shows (table 1), prolongation along with the time, model group nonenzymatic glycosylation product produces and increases gradually, the test product group that is subject to of each concentration all has the effect of Profilin matter nonenzymatic glycosylation, each concentration be subject to test product group and the comparison of high Fructus Momordicae charantiae content group, the effect of its Profilin matter nonenzymatic glycosylation is more remarkable, and be concentration-inhibitory action positive correlation, wherein be subject to test product high dose group to suppress the generation of external protein non-enzyme glycosylation completely, be subject to test product and high Fructus Momordicae charantiae content group comparative effectiveness remarkable.
Table 1 is subject to the impact of the different incubation times of test product on protein non-enzyme glycosylation
Note:
*compare P < 0.01 with blank group;
△ △compare P < 0.01 with model group;
▲ ▲compare P < 0.01 with high Fructus Momordicae charantiae content group.3.2 impacts that AGEs in the diabetic mice heart, liver, kidney is generated
Be subject to test product to generate and there is inhibitory action significantly AGEs in diabetic mice tissue, and present control of the concentration effect positive correlation, be subject to test product and high Fructus Momordicae charantiae content group comparative effectiveness remarkable.In Table 2.
The impact (AUF/mg) that table 2 is generated AGEs in the diabetic mice heart, liver, kidney by test product
Note:
*compare P < 0.05 with blank group;
*compare P < 0.01 with blank group;
△compare P < 0.05 with model group;
△ △compare P < 0.01 with model group;
▲compare P < 0.05 with high Fructus Momordicae charantiae content group;
▲ ▲compare P < 0.01 with high Fructus Momordicae charantiae content group.
3.3 impacts on hyperglycemia model mice fasting glucose
Before modeling, getting at random 10 animals survey fasting glucose is 6.0 ± 1.1mmol/L, from table 3, after modeling type, respectively organize mice fasting glucose and obviously raise (18.6 ± 1.71mmol/L), have significance (P < 0.01) with comparing difference before modeling, model establishment is described.After test, be subject to each dosage group mice fasting glucose of test product all lower than model and high Fructus Momordicae charantiae content group, difference has significance, be subject to each dosage group blood glucose rate of descent of test product to be all greater than model and high Fructus Momordicae charantiae content group, difference and matched group relatively have significance, illustrate that tested material has and falls hypoglycemic effect alloxan hyperglycemia model mice, and effect is significantly better than high Fructus Momordicae charantiae content group.
Table 3 is on the impact of hyperglycemia model mice fasting glucose (mmol/L)
Note:
△compare P < 0.05 with model group;
△ △compare P < 0.01 with model group;
▲compare P < 0.05 with high Fructus Momordicae charantiae content group;
▲ ▲compare P < 0.01 with high Fructus Momordicae charantiae content group.
3.4 impacts on alloxan hyperglycemia model glucose tolerance in mice:
Be subject to each dosage treated animal of test product to give 0h, 0.5h after glucose solution, 2h blood glucose value all lower than model group and high Fructus Momordicae charantiae content group, difference has significance, in Table 4; Be less than model and high Fructus Momordicae charantiae content group to area under rear each dosage group glucose curve of sugar, difference has significance, in Table 5; Prompting tested material has the effect of rising carbohydrate tolerance to hyperglycemia model mice, and effect is significantly better than high Fructus Momordicae charantiae content group.
Table 4 is given the impact (mmol/L) of the rear blood glucose of sugar on hyperglycemia model mice
Note:
△compare P < 0.05 with model group;
△ △compare P < 0.01 with model group;
▲compare P < 0.05 with high Fructus Momordicae charantiae content group;
▲ ▲compare P < 0.01 with high Fructus Momordicae charantiae content group.
Table 5 is given the impact (hmmol/L) of the rear blood glucose of sugar on hyperglycemia model mice
Note:
△ △compare P < 0.01 with model group;
▲compare P < 0.05 with high Fructus Momordicae charantiae content group;
▲ ▲compare P < 0.01 with high Fructus Momordicae charantiae content group.
In sum, the present invention be take the Chinese medicine composition that Fructus Momordicae charantiae is primary raw material and is compared with existing, there is hypoglycemic effect more significantly, the more important thing is, compositions of the present invention is effective Profilin matter nonenzymatic glycosylation end-product (advanced glycation end products aspect control diabetic complication, AGEs) formation, evident in efficacy to diabetic complication.
Specific embodiment
Following examples are to use Chinese medicine composition preparation of the present invention to prevent and treat the example of the preparation of diabetes.
Embodiment mono-
1. take Radix Notoginseng extract 70g, Radix Panacis Quinquefolii extract 90g, chromium picolinate 0.45g, Fructus Momordicae charantiae extract 30g, starch 209.55g bacterium inspection respectively, qualified standby.
2. by each material mix homogeneously described in 1, then with fully-automatic capsule machine, be filled to capsule, every capsules content is 400mg, makes altogether 1000.
3. by gained capsule granulate, polishing, check, packing in 2.
Embodiment bis-
1. by Radix Notoginseng extract 60g, Radix Panacis Quinquefolii extract 80g, chromium picolinate 0.41g, Fructus Momordicae charantiae extract 50g, starch 209.59g bacterium inspection respectively, qualified standby.
2. by each material mix homogeneously described in 1, then with fully-automatic capsule machine, be filled to capsule, every capsules content is 400mg, makes altogether 1000.
3. by gained capsule granulate, polishing, check, packing in 2.
Embodiment tri-
1. take Radix Notoginseng extract 70g, Radix Panacis Quinquefolii extract 90g, chromium picolinate 0.35g, Fructus Momordicae charantiae extract 30g, 193.65g starch, 15g microcrystalline Cellulose and 1g magnesium stearate, standby after bacterium inspection respectively;
2. by each material described in step 1 (except magnesium stearate) mix homogeneously, with 60%～80% alcohol granulation, dry, granulate, adds magnesium stearate, mixes, and is pressed into 1000, the tablet of prevent diabetes.
Embodiment tetra-
1. take Radix Notoginseng extract 70g, Radix Panacis Quinquefolii extract 90g, chromium picolinate 0.35g, Fructus Momordicae charantiae extract 50g, 174.65g starch, 15g microcrystalline Cellulose, standby after bacterium inspection respectively;
2. by each material mix homogeneously described in step 1, with 60%～80% alcohol granulation, dry, granulate, is distributed into 1000 bags of the granules of prevent diabetes.
Claims (10)
1. the pharmaceutical composition of a prevention and treatment diabetes and complication thereof, it is characterized in that, it is comprised of the component of following weight proportion: the Radix Notoginseng extract of 40～120 parts, the Radix Panacis Quinquefolii extract of 60～180 parts, the chromium picolinate of 0.2～0.6 part and the Fructus Momordicae charantiae extract of 10～70 parts.
2. pharmaceutical composition claimed in claim 1, it is characterized in that, described Chinese medicine composition is comprised of the component of following weight proportion: the Radix Notoginseng extract of 40～100 parts, the Radix Panacis Quinquefolii extract of 80～150 parts, the chromium picolinate of 0.3～0.6 part and the Fructus Momordicae charantiae extract of 25～60 parts.
3. pharmaceutical composition claimed in claim 2, it is characterized in that, described Chinese medicine composition is comprised of the component of following weight proportion: the Radix Notoginseng extract of 60～80 parts, the Radix Panacis Quinquefolii extract of 80～100 parts, the chromium picolinate of 0.4～0.5 part and the Fructus Momordicae charantiae extract of 25～50 parts.
4. pharmaceutical composition claimed in claim 3, is characterized in that, described Chinese medicine composition is comprised of the component of following weight proportion: the Radix Notoginseng extract of 60 parts, the Radix Panacis Quinquefolii extract of 80 parts, the chromium picolinate of 0.41 part and the Fructus Momordicae charantiae extract of 50 parts.
5. pharmaceutical composition claimed in claim 3, is characterized in that, described Chinese medicine composition is comprised of the component of following weight proportion: the Radix Notoginseng extract of 75 parts, the Radix Panacis Quinquefolii extract of 80 parts, the chromium picolinate of 0.5 part and the Fructus Momordicae charantiae extract of 35 parts.
6. pharmaceutical composition claimed in claim 3, is characterized in that, described Chinese medicine composition is comprised of the component of following weight proportion: the Radix Notoginseng extract of 70 parts, the Radix Panacis Quinquefolii extract of 95 parts, the chromium picolinate of 0.45 part and the Fructus Momordicae charantiae extract of 25 parts.
7. for preventing and treat a preparation for diabetes and complication thereof, it is characterized in that: contain pharmaceutical composition claimed in claim 1 and conventional adjuvant, wherein said adjuvant accounts for 15%～65% of total formulation weight amount.
8. preparation claimed in claim 7, is characterized in that: described adjuvant is one or more in disintegrating agent, filler, lubricant, correctives or excipient.
9. preparation claimed in claim 8, is characterized in that: described disintegrating agent is starch; Described filler is starch or dextrin; Described lubricant is magnesium stearate; Described correctives is lactose; Described excipient is microcrystalline Cellulose.
10. preparation claimed in claim 7, is characterized in that: described preparation formulation is hard capsule, tablet or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310562432.7A CN103550281B (en) | 2013-11-12 | 2013-11-12 | The pharmaceutical composition of a kind of prevention and therapy diabetes and complication thereof and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310562432.7A CN103550281B (en) | 2013-11-12 | 2013-11-12 | The pharmaceutical composition of a kind of prevention and therapy diabetes and complication thereof and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103550281A true CN103550281A (en) | 2014-02-05 |
| CN103550281B CN103550281B (en) | 2015-11-18 |
Family
ID=50004753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310562432.7A Active CN103550281B (en) | 2013-11-12 | 2013-11-12 | The pharmaceutical composition of a kind of prevention and therapy diabetes and complication thereof and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103550281B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105412291A (en) * | 2015-12-09 | 2016-03-23 | 贵州瑞和制药有限公司龙里药厂 | Application of Shuganning to preparation of medicine for treating diabetic neuropathy and complications |
| CN107050078A (en) * | 2017-02-04 | 2017-08-18 | 文山金七药业有限公司 | A kind of pseudo-ginseng extract soft capsule and preparation method thereof |
| CN114324662A (en) * | 2021-12-30 | 2022-04-12 | 中南大学 | Serum biomarker for diagnosing or preventing diabetes, detection reagent and application thereof |
| CN114558051A (en) * | 2022-03-14 | 2022-05-31 | 北京瑞草科技有限公司 | Chinese medicinal composition for treating diabetes and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102871116A (en) * | 2011-07-14 | 2013-01-16 | 重庆市生物技术研究所有限责任公司 | Traditional Chinese medicine type blood sugar-lowering health care food |
| CN103082298A (en) * | 2013-01-17 | 2013-05-08 | 吉林省中药制剂工程研究中心有限公司 | Health-care food for reducing blood glucose in assisted mode and preparation method thereof |
-
2013
- 2013-11-12 CN CN201310562432.7A patent/CN103550281B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102871116A (en) * | 2011-07-14 | 2013-01-16 | 重庆市生物技术研究所有限责任公司 | Traditional Chinese medicine type blood sugar-lowering health care food |
| CN103082298A (en) * | 2013-01-17 | 2013-05-08 | 吉林省中药制剂工程研究中心有限公司 | Health-care food for reducing blood glucose in assisted mode and preparation method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105412291A (en) * | 2015-12-09 | 2016-03-23 | 贵州瑞和制药有限公司龙里药厂 | Application of Shuganning to preparation of medicine for treating diabetic neuropathy and complications |
| CN107050078A (en) * | 2017-02-04 | 2017-08-18 | 文山金七药业有限公司 | A kind of pseudo-ginseng extract soft capsule and preparation method thereof |
| CN114324662A (en) * | 2021-12-30 | 2022-04-12 | 中南大学 | Serum biomarker for diagnosing or preventing diabetes, detection reagent and application thereof |
| CN114558051A (en) * | 2022-03-14 | 2022-05-31 | 北京瑞草科技有限公司 | Chinese medicinal composition for treating diabetes and preparation method thereof |
| CN114558051B (en) * | 2022-03-14 | 2023-07-04 | 浙江新昌天然保健品有限公司 | Chinese medicinal composition for treating diabetes and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103550281B (en) | 2015-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102600212B (en) | Medicinal health product for immunity enhancement and adjuvant treatment of tumor | |
| CN102048959A (en) | Dendrobium candidum compound preparation capable of regulating function of human body in two-way manner and preparation method thereof | |
| JP2018502079A (en) | Eurycoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
| CN104688822A (en) | Tablet for assisting to reduce blood glucose and preparation method | |
| CN103550281B (en) | The pharmaceutical composition of a kind of prevention and therapy diabetes and complication thereof and preparation thereof | |
| CN105079089A (en) | Preparation method of kudzuvine root and bitter gourd health-care food assisting in reducing blood glucose | |
| CN103405655B (en) | Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof | |
| CN104107324A (en) | Traditional Chinese medicine compound preparation for treating type II diabetes mellitus and preparation method of traditional Chinese medicine compound preparation | |
| CN104840777A (en) | Diabetes treating traditional Chinese medicine preparation and preparation method thereof | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN105685543A (en) | Functional sheet for adjuvant treatment on diabetes type II and production method thereof | |
| CN1297290C (en) | Medicinal composition for treating coronary heart disease and stenocardia and its preparation method | |
| CN107137416B (en) | A kind of pharmaceutical composition preventing and treating non-small cell lung cancer | |
| CN103239470B (en) | Dual-mushroom polysaccharide composition containing coprinus comatus polysaccharide and lentinan as well as preparation method and application thereof | |
| CN102784237A (en) | Pharmaceutical composition for preventing or treating diabetic complications | |
| CN102178718B (en) | Preparation used for treating diabetes mellitus and preventively treating heart cerebrovascular disease | |
| CN103622027A (en) | Health-care food composition for reducing blood glucose | |
| CN107744571A (en) | A kind of pharmaceutical composition for improving blood vessel endothelium dysfunction and its production and use | |
| CN102526198A (en) | Medicine with cinnamon and chromium as additives and preparation method for health care product | |
| CN102861114A (en) | Kiwi fruit extract and extraction method and application thereof | |
| CN106138900A (en) | Auxiliary treats hyperglycemia and the compositions of diabetic complication and application thereof | |
| CN101537079B (en) | Pharmaceutical composition or health-care product for improving sleeping and delaying senility and preparation method thereof | |
| CN101991757B (en) | Chinese medicinal composition for reinforcing kidney and supporting yang and preparation method thereof | |
| CN100546621C (en) | A kind of new purposes of known drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |